BioSpace News Archive

Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest aggregate and particle identification system, called Aura™.

If scientists understood how Alzheimer’s disease starts, they might have a better handle on how to stop it. That’s the premise behind a new $40.5 million collaborative research center in Seattle to build high-resolution maps of Alzheimer’s patients’ brains and identify how their neurons and other brain cells differ from those of healthy people.

Aldevron, a leading provider of products and services for the biotechnology industry, today announced an agreement with Ziopharm Oncology to produce plasmid DNA for T cell therapy of solid tumors.

Jellagen, a leader in advanced collagen biomaterials from marine sources, announces the closing of a £1.9m seed equity round to pursue development of products for therapeutic and medical device applications

The following resolutions were passed at Calliditas Therapeutics AB (publ) (“Calliditas”) annual general meeting held today, on June 25, 2020, in Stockholm.

Specialist Direct, the market leader in providing telepathology solutions for OPOs, and Grundium, a global leader in advanced imaging technology, formally announced their exclusive partnership for the Organ Procurement Organization industry.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on the health security market, announced the deliveries of oral TPOXX® to the U.S. Department of Health and Human Services.

Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of an additional 3,375,000 shares of common stock pursuant to the full exercise of the underwriters’ option to purchase additional shares from Leap’s previously announc

Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced the publication of a new research paper released today in Frontiers in Bioengineering and Biotechnology . This article describes an innovative and easy-to-implement procedure which will streamline the manufacturing of allogeneic ‘off-the-shelf’ CAR T-cell therapies.

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today reported financial results for its fiscal year ended March 31, 2020 and provided an update on recent developments.